ArticleHaematologica2022

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.

Anthony R Mato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.